You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

907 Results
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
New Drug Funding Program
    Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zolbetuximab,
raltitrexed,
oxaliplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Guidelines and Advice
Status: Current
ID: 5-2
Version: 2
Oct 2023
Document
New
Dec 2025
Document
New
Dec 2025
Document
New
Dec 2025
Document
New
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bevacizumab,
raltitrexed,
oxaliplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Statistical Reports
Ontario Cancer Statistics 2024 is the fifth in a series of reports that provide comprehensive information on the burden of cancer in Ontario....
Feb 2025
Document
New
Dec 2025
Cette plateforme contient des outils et des ressources pour les prestataires de soins primaires, les colposcopistes et d’autres professionnels de la...
Lung cancer screening through the Ontario Lung Screening Program is available for people who qualify at the following hospitals in Ontario. People...
The Ontario Cancer Registry SEER*Stat Package contains de-identified Ontario cancer data files derived from the Ontario Cancer Registry, the SEER*...

Pages